Get the Stockscreener App
0.5121
5.27%
0.0207
Plus Therapeutics Inc stock is traded at $0.5121, with a volume of 7.56M.
It is up +5.27% in the last 24 hours and down -34.93% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$0.4914
Open:
$0.505
24h Volume:
7.56M
Relative Volume:
0.28
Market Cap:
$50.82M
Revenue:
-
Net Income/Loss:
$-12.89M
P/E Ratio:
-0.2024
EPS:
-2.53
Net Cash Flow:
$-11.95M
1W Performance:
+13.44%
1M Performance:
-34.93%
6M Performance:
-67.05%
1Y Performance:
-63.31%
1-Day Range:
$0.50
$0.56
1-Week Range:
$0.385
$0.56
52-Week Range:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.512 | 48.78M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.39 | 101.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
457.38 | 59.25B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.94 | 60.77B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
759.82 | 45.95B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
344.21 | 37.61B | 3.81B | -644.79M | -669.77M | -6.24 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
What is Plus Therapeutics Inc.’s valuation compared to sectorJuly 2025 Highlights & Consistent Profit Focused Trading Strategies - beatles.ru
Can machine learning forecast Plus Therapeutics Inc. recovery2025 Price Action Summary & High Return Trade Guides - Newser
Tick level data insight on Plus Therapeutics Inc. volatilityM&A Rumor & AI Driven Price Forecasts - Newser
Can Plus Therapeutics Inc. hit a new high this monthJuly 2025 Catalysts & Safe Entry Momentum Stock Tips - Newser
Can Plus Therapeutics Inc. sustain its profitabilityEarnings Trend Report & Long-Term Safe Return Strategies - خودرو بانک
What is Plus Therapeutics Inc. s P E ratio telling usMarket Sentiment Report & Fast Gaining Stock Reports - خودرو بانک
Will Plus Therapeutics Inc. stock hit new highs in YEAR2025 Growth vs Value & Real-Time Market Sentiment Alerts - خودرو بانک
Can Plus Therapeutics Inc. benefit from deglobalizationJuly 2025 Institutional & Reliable Price Action Trade Plans - خودرو بانک
Growth Value: What is Plus Therapeutics Inc.’s valuation compared to sectorQuarterly Portfolio Review & Accurate Entry/Exit Alerts - خودرو بانک
Live market analysis of Plus Therapeutics Inc.Quarterly Growth Report & Capital Efficient Trading Techniques - Newser
What’s the recovery path for long term holders of Plus Therapeutics Inc. - Newser
Navigating Biotech Innovation Amid Sector Volatility: High-Conviction Opportunities in 2025 - AInvest
Is a relief rally coming for Plus Therapeutics Inc. holdersJuly 2025 Price Swings & Reliable Momentum Entry Alerts - Newser
Plus Therapeutics Inc. recovery potential after sell offTake Profit & Precise Swing Trade Entry Alerts - Newser
Plus Therapeutics Inc. stock trendline breakdownWeekly Loss Report & Free Real-Time Market Sentiment Alerts - Newser
Plus Therapeutics, Inc. shares rise 2.22% premarket after HUTCHMED highlights clinical data at conference. - AInvest
Backtesting results for Plus Therapeutics Inc. trading strategiesGold Moves & Safe Capital Investment Plans - Newser
Should you wait for a breakout in Plus Therapeutics Inc.2025 Big Picture & Daily Stock Trend Watchlist - Newser
How to read the order book for Plus Therapeutics Inc.Quarterly Market Summary & Verified Chart Pattern Signals - Newser
Visualizing Plus Therapeutics Inc. stock with heatmapsJuly 2025 Reactions & Verified Swing Trading Watchlist - Newser
Is Plus Therapeutics Inc. building a consolidation baseJuly 2025 Sentiment & Weekly Market Pulse Alerts - Newser
Multi asset correlation models including Plus Therapeutics Inc.Profit Target & AI Enhanced Trading Alerts - Newser
Forecasting Plus Therapeutics Inc. price range with options dataWeekly Risk Summary & Precise Trade Entry Recommendations - Newser
How to integrate Plus Therapeutics Inc. into portfolio analysis toolsOil Prices & AI Driven Price Forecasts - Newser
Screener Results Flag Plus Therapeutics Inc. as Oversold2025 Risk Factors & Community Verified Watchlist Alerts - beatles.ru
Plus Therapeutics, Inc. shares rise 1.96% intraday after AC Immune's operational efficiencies and pipeline focus. - AInvest
Using data tools to time your Plus Therapeutics Inc. exitQuarterly Earnings Summary & Smart Swing Trading Techniques - Newser
Published on: 2025-09-04 04:06:08 - Newser
Building trade automation scripts for Plus Therapeutics Inc.Jobs Report & Verified Swing Trading Watchlist - Newser
What data driven models say about Plus Therapeutics Inc.’s future2025 Stock Rankings & Free Verified High Yield Trade Plans - Newser
How to forecast Plus Therapeutics Inc. trends using time seriesJuly 2025 Market Mood & Technical Pattern Recognition Alerts - Newser
Chart overlay techniques for tracking Plus Therapeutics Inc.July 2025 Levels & Real-Time Chart Breakout Alerts - Newser
Plus Therapeutics shares rise 4.68% intraday after announcing participation in H.C. Wainwright 27th Annual Global Investment Conference. - AInvest
Plus Therapeutics stock rating upgraded to Buy by D. Boral Capital - Investing.com Canada
This BorgWarner Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday - Benzinga
Market reaction to Plus Therapeutics Inc.’s recent news2025 Sector Review & Daily Chart Pattern Signal Reports - Newser
Custom watchlist performance reports with Plus Therapeutics Inc2025 Historical Comparison & Weekly Watchlist for Hot Stocks - Newser
Plus Therapeutics Inc. stock momentum explainedMarket Weekly Review & Expert Curated Trade Ideas - Newser
What Fibonacci levels say about Plus Therapeutics Inc. rebound2025 AllTime Highs & Free Reliable Trade Execution Plans - Newser
What technical models suggest about Plus Therapeutics Inc.’s comebackWeekly Stock Analysis & Free Community Supported Trade Ideas - Newser
What moving averages say about Plus Therapeutics Inc.2025 Geopolitical Influence & Weekly Top Performers Watchlists - Newser
Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference - MarketScreener
Plus Therapeutics, Inc. to Participate in H.C. Wainwright 27th Annual Global Investment Conference 2025 - Quiver Quantitative
CNS Cancer Drug Developer Plus Therapeutics Featured at Major H.C. Wainwright Investment Conference - Stock Titan
Ranking Plus Therapeutics Inc. among high performing stocks via toolsJuly 2025 Macro Moves & Real-Time Volume Triggers - Newser
What is Plus Therapeutics Inc. s revenue forecastTrade Performance Summary & High Accuracy Swing Trade Signals - خودرو بانک
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):